Cel-Sci Corp Dossier - Source-backed chat

Cel-Sci Corp

CVMNYSE

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.69

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.09Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $36.8M

Enterprise Value $35.9M

Shares Outstanding 17.6M diluted

Next Earnings Date29 Dec 2026

Last ex-dividend28 Aug 1996

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

CEL-SCI Corporation (NYSE American: CVM) is a late-stage clinical biotechnology company focused on its lead cancer immunotherapy candidate, Multikine (Leukocyte Interleukin, Injection). The company is pursuing a dual-track regulatory strategy: initiating a 212-patient U.S. FDA confirmatory registration study in patients with newly diagnosed locally advanced head and neck cancer (specifically those with low PD-L1 expression and no lymph node involvement), while simultaneously advancing commercialization in Saudi Arabia via a 50/50 revenue-sharing partnership with Saudi Amarox. While the clinical data from its prior Phase 3 study demonstrated a compelling 73% five-year overall survival rate in the target population compared to 45% for standard of care alone, CEL-SCI faces severe financial constraints. With only $1.9 million in cash as of March 31, 2026, and an estimated confirmatory study cost of $30 million to $35 million, the company is highly dependent on continuous dilutive equity offerings (such as its recent $2.5 million offering in June 2026) and potential milestone payments. Consequently, a 'Hold' rating is recommended, balancing the high-upside clinical potential of Multikine against extreme near-term liquidity and going concern risks.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.00

Mean target$12.50

High · most bullish analyst$15.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

CEL-SCI experiences severe delays in enrolling the 212-patient confirmatory study due to capital constraints or clinical site bottlenecks. The Saudi SFDA rejects or significantly delays the Breakthrough Medicine Designation, stalling near-term commercialization plans. Continuous dilutive equity offerings at depressed valuations heavily dilute existing shareholders, and the company is unable to raise the $30 million to $35 million required to complete the confirmatory study, leading to insolvency or a distressed fire sale of intellectual property.

Base CaseCentral scenario

CEL-SCI successfully initiates its 212-patient confirmatory registration study in Summer/Fall 2026. The company continues to fund operations through incremental, highly dilutive best-efforts equity offerings and potential upfront/milestone payments from regional partnerships like Saudi Amarox. Saudi Arabia SFDA grants Breakthrough Medicine Designation, triggering early commercialization and local distribution rights, which provides non-dilutive revenue to offset U.S. clinical trial costs. The stock trades in a volatile range reflecting clinical milestones and cash burn.

Bull CaseUpside scenario

The bull case centers on the successful execution of Cel-Sci's 212-patient confirmatory Phase 3 registration study for its lead immunotherapy, Multikine, in newly diagnosed head and neck cancer patients with low or zero PD-L1 expression. In this target population, Multikine followed by standard of care demonstrated a 73% 5-year survival rate versus 45% with standard of care alone (hazard ratio of 0.35). Successful trial execution and potential early accelerated approval based on pre-surgical tumor response data could unlock significant commercial value, with analysts projecting a consensus price target of $25.00 to $42.50.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong clinical signal in the target population, showing a 73% five-year overall survival rate with Multikine versus 45% with standard of care alone (hazard ratio of 0.35).
FDA-concurred design for the 212-patient confirmatory registration study, focusing exclusively on the high-responder patient population (low PD-L1, no lymph node involvement).
Strategic partnership with Saudi Amarox providing a 50/50 revenue-sharing model in Saudi Arabia and options for expansion into other Gulf Cooperation Council (GCC) countries.
Orphan Drug designation from the FDA for Multikine as neoadjuvant therapy in squamous cell carcinoma of the head and neck.

Key Investment Risks

Severe liquidity constraints, with only $1.9 million in cash as of March 31, 2026, and an active 'going concern' warning from auditors.
High cost of the planned confirmatory registration study, estimated at $30 million to $35 million, requiring substantial additional financing.
Extreme dilution risk, as evidenced by frequent best-efforts public offerings (e.g., $7.2 million in May 2026 and $2.5 million in June 2026) to fund short-term working capital.
Binary regulatory risk; Multikine has not yet been approved for sale by the FDA or any other global regulatory agency, and safety/efficacy has not been fully established.

Thesis Invalidation Triggers

Inability to secure sufficient capital to initiate or sustain the 212-patient confirmatory registration study.
Rejection of the Breakthrough Medicine Designation by the Saudi Food and Drug Authority (SFDA).
Clinical trial protocol deviations or safety signals that halt the confirmatory study.
Delisting from the NYSE American exchange due to failure to meet minimum stockholders' equity or share price requirements.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.